http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Park Yeong-Ju,Hwang Unsik,Park Suyeon,Sim Sol,Jeong Soyeon,Park Misun,Kang Minji,Lee Youngsoo,Song Youngju,Park Hoon,Suh Hee-Jae 한국응용생명화학회 2021 Applied Biological Chemistry (Appl Biol Chem) Vol.64 No.1
Compound K (CK; 20-O-β-(d-glucopyranosyl)-20(S)-protopanaxadiol) is one of the metabolites of ginsenosides contained in red ginseng (RG) and is known to have high bioavailability. This study aimed to establish the optimal conditions for enzyme treatment to convert ginsenosides from RG extract to CK, and to prove the characteristics of bioconverted red ginseng (BRG) extract. CK was not detected in unenzyme-treated RG extract, and in the single-step enzyme treatment, it was produced at less than 4.58 mg/g only in treatment group with Pyr-flo or Sumizyme AC (at 50 °C for 48 h). The highest yield of CK (14.32 mg/g) was obtained by Ultimase MFC treatment at 50 °C for 48 h after treatment with a mixture of Pyr-flo and Rapidase at 50 °C for 24 h. Total polyphenol, 2,2-diphenyl-1-picrylhydrazyl (DPPH), and 2,2-azinobis-(3-ethylbenzothiazoline-6-sulfonic acid)) (ABTS) radical scavenging activity were higher in BRG than in RG (p < 0.5). High-fat diet (HD) rat fed 1% BRG had significantly lower body weight, heart weight, fat pads (periosteal fat, epididymal fat), serum glucose levels, and hepatic triglyceride levels than those HD rat fed 1% RG (p < 0.05). In conclusion, the sequential enzymatic bioconversion was produces higher CK in RG root extract than single-step enzyme treatment.
Yang Misun,Kim Jee Ah,Jo Heui Seung,Park Jong-Ho,Ahn So Yoon,Sung Se In,Park Won Soon,Cho Hye-Won,Kim Jeong-Min,Park Mi-Hyun,Park Hyun-Young,Jang Ja-Hyun,Chang Yun Sil 대한의학회 2024 Journal of Korean medical science Vol.39 No.36
Background: Achieving a definitive genetic diagnosis of unexplained multiple congenital anomalies (MCAs) in neonatal intensive care units (NICUs) infants is challenging because of the limited diagnostic capabilities of conventional genetic tests. Although the implementation of whole genome sequencing (WGS) has commenced for diagnosing MCAs, due to constraints in resources and faculty, many NICUs continue to utilize chromosomal microarray (CMA) and/or karyotyping as the initial diagnostic approach. We aimed to evaluate the diagnostic efficacy of WGS in infants with MCAs who have received negative results from karyotyping and/or CMA. Methods: In this prospective study, we enrolled 80 infants with MCAs who were admitted to a NICU at a single center and had received negative results from CMA and/or karyotyping. The phenotypic characteristics were classified according to the International Classification of Diseases and the Human Phenotype Ontology. We assessed the diagnostic yield of trioWGS in infants with normal chromosomal result and explored the process of diagnosing by analyzing both phenotype and genotype. Also, we compared the phenotype and clinical outcomes between the groups diagnosed with WGS and the undiagnosed group. Results: The diagnostic yield of WGS was 26% (21/80), of which 76% were novel variants. There was a higher diagnostic yield in cases of craniofacial abnormalities, including those of the eye and ear, and a lower diagnostic yield in cases of gastrointestinal and genitourinary abnormalities. In addition, higher rates of rehabilitation therapy and gastrostomy were observed in WGS-diagnosed infants than in undiagnosed infants. Conclusion: This prospective cohort study assessed the usefulness of trio-WGS following chromosomal analysis for diagnosing MCAs in the NICU and revealed improvements in the diagnostic yield and clinical utility of WGS.
Park, Min Hee,Lee, Misun,Nam, Geewoo,Kim, Mingeun,Kang, Juhye,Choi, Byung Jo,Jeong, Min Seock,Park, Kang Ho,Han, Wan Hui,Tak, Eunyoung,Kim, Min Sun,Lee, Juri,Lin, Yuxi,Lee, Young-Ho,Song, Im-Sook,Choi National Academy of Sciences 2019 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF Vol.116 No.47
<P><B>Significance</B></P><P>Microglial dysfunction accompanying the loss of phagocytic ability and the overexpression of neurotoxic factors presents a positive-feedback loop that contributes to the rapid progression of neurodegeneration. Termination of this cycle is considered a promising strategy to halt the progression of neurodegenerative diseases, including Alzheimer’s disease; however, effective chemical reagents for this purpose have been very limited. Herein, we report a compact synthetic molecule capable of restoring microglial dysfunction and improving cognitive function. Our in-depth studies of such a molecular entity could be beneficial toward the urgent global search for a new and effective treatment of neurodegenerative disorders.</P><P>As a central feature of neuroinflammation, microglial dysfunction has been increasingly considered a causative factor of neurodegeneration implicating an intertwined pathology with amyloidogenic proteins. Herein, we report the smallest synthetic molecule (<I>N</I>,<I>N</I>′-diacetyl-<I>p</I>-phenylenediamine [DAPPD]), simply composed of a benzene ring with 2 acetamide groups at the <I>para</I> position, known to date as a chemical reagent that is able to promote the phagocytic aptitude of microglia and subsequently ameliorate cognitive defects. Based on our mechanistic investigations in vitro and in vivo, 1) the capability of DAPPD to restore microglial phagocytosis is responsible for diminishing the accumulation of amyloid-β (Aβ) species and significantly improving cognitive function in the brains of 2 types of Alzheimer’s disease (AD) transgenic mice, and 2) the rectification of microglial function by DAPPD is a result of its ability to suppress the expression of NLRP3 inflammasome-associated proteins through its impact on the NF-κB pathway. Overall, our in vitro and in vivo investigations on efficacies and molecular-level mechanisms demonstrate the ability of DAPPD to regulate microglial function, suppress neuroinflammation, foster cerebral Aβ clearance, and attenuate cognitive deficits in AD transgenic mouse models. Discovery of such antineuroinflammatory compounds signifies the potential in discovering effective therapeutic molecules against AD-associated neurodegeneration.</P>
Doping effects of multiferroic manganitesYMn0.9X0.1O3(X=Al, Ru, and Zn)
Park, Junghwan,Kang, Misun,Kim, Jiyeon,Lee, Seongsu,Jang, Kwang-Hyun,Pirogov, A.,Park, J.-G.,Lee, Changhee,Park, S.-H.,Kim, Hyoung Chan American Physical Society 2009 Physical review. B, Condensed matter and materials Vol.79 No.6
One-Nanometer-Scale Size-Controlled Synthesis of Monodisperse Magnetic Iron Oxide Nanoparticles
Park, Jongnam,Lee, Eunwoong,Hwang, Nong-Moon,Kang, Misun,Kim, Sung Chul,Hwang, Yosun,Park, Je-Geun,Noh, Han-Jin,Kim, Jae-Young,Park, Jae-Hoon,Hyeon, Taeghwan WILEY-VCH Verlag 2005 Angewandte Chemie Vol.44 No.19
<B>Graphic Abstract</B> <P>Accurate to size: Monodisperse magnetic iron oxide nanoparticles with a continuous size spectrum of 6–13 nm have been synthesized by a procedure similar to seed-mediated growth and characterized by transmission electron microscopy (see picture) and magnetic measurements. This method yields monodisperse nanoparticles directly without a size-selection process. <img src='wiley_img/14337851-2005-44-19-ANIE200461665-content.gif' alt='wiley_img/14337851-2005-44-19-ANIE200461665-content'> </P>
Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes
Park, Misun,Yoon, Young-sup The Korean Society of Cardiology 2018 Korean Circulation Journal Vol.48 No.11
<P>Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), which are collectively called pluripotent stem cells (PSCs), have emerged as a promising source for regenerative medicine. Particularly, human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have shown robust potential for regenerating injured heart. Over the past two decades, protocols to differentiate hPSCs into CMs at high efficiency have been developed, opening the door for clinical application. Studies further demonstrated therapeutic effects of hPSC-CMs in small and large animal models and the underlying mechanisms of cardiac repair. However, gaps remain in explanations of the therapeutic effects of engrafted hPSC-CMs. In addition, bioengineering technologies improved survival and therapeutic effects of hPSC-CMs in vivo. While most of the original concerns associated with the use of hPSCs have been addressed, several issues remain to be resolved such as immaturity of transplanted cells, lack of electrical integration leading to arrhythmogenic risk, and tumorigenicity. Cell therapy with hPSC-CMs has shown great potential for biological therapy of injured heart; however, more studies are needed to ensure the therapeutic effects, underlying mechanisms, and safety, before this technology can be applied clinically.</P>